MongoDB downgraded, Block upgraded: Wall Street's top analyst calls

Core Viewpoint - Several firms have initiated coverage on various companies with positive ratings, indicating optimism about their growth potential and market positioning Group 1: Company Initiations - RBC Capital initiated coverage of Iqvia (IQV) with an Outperform rating and a price target of $221, citing an expected increase in clinical trial activity into 2026 [1] - RBC Capital also initiated coverage of Ormat Technologies (ORA) with an Outperform rating and a price target of $130, believing geothermal energy is well positioned to meet the demands of hyperscalers and transactions [1] - Oppenheimer initiated coverage of Once Upon a Farm (OFRM) with an Outperform rating and a price target of $35, suggesting over 45% upside from current levels, and highlighting it as an attractive small-cap growth story in the food sector [1] - Jefferies initiated coverage of SpyGlass Pharma (SGP) with a Buy rating and a price target of $62, noting a 75% probability of success for its Phase 3 study for glaucoma, expected to report in late 2027 [1] - RBC Capital initiated coverage of Medpace (MEDP) with an Outperform rating and a price target of $522, recognizing it as the most efficient contract research organization (CRO) per employee, with strong leverage to biopharma markets [1]